• New potential drug target for Alzheimer'

    From ScienceDaily@1:317/3 to All on Wednesday, May 24, 2023 22:30:30
    New potential drug target for Alzheimer's disease
    Rensselaer researchers find new potential drug target for Alzheimer's
    disease

    Date:
    May 24, 2023
    Source:
    Rensselaer Polytechnic Institute
    Summary:
    Tau protein is implicated in many neurogenerative diseases,
    including Alzheimer's. New findings point to a new potential drug
    target to slow the progress of the disease: the enzymes responsible
    for sulfation called heparan sulfate 3-O transferases.


    Facebook Twitter Pinterest LinkedIN Email

    ==========================================================================
    FULL STORY ========================================================================== Chunyu Wang, Ph.D., professor of biological sciences at Rensselaer
    Polytechnic Institute, has added to his body of research on Alzheimer's
    disease with significant findings in Angewandte Chemie.

    Together with his team, which includes first author and Rensselaer
    doctoral student Dylan Mah, Wang performed the most comprehensive study
    to date of the interactions between ApoE, or Apolipoprotein E,
    and heparan sulfate (HS).

    ApoE is a protein that combines with fats to transport cholesterol
    throughout the body. Heparan sulfate is a sugar molecule present on cell surfaces that plays a key role in cellular communication. A variant
    of ApoE, ApoE4, is the most significant genetic risk for late-onset
    Alzheimer's disease.

    "It's tremendously interesting to explore why ApoE4 can increase
    Alzheimer's risk," said Wang.

    Wang's team investigated not only ApoE4, but ApoE3, the most common
    ApoE genotype and two protective isoform ApoE2 and ApoE Christchurch,
    as well. They discovered that the 3-O-sulfo (3-O-S) modification of HS
    was important for ApoE/HS interactions. All isoforms of ApoE recognized
    3-O-S, but the differences in their strength of interactions correlated
    with Alzheimer's disease risk.

    "In the initial glycan array experiment, which is basically a chip with a collection of different heparan sulfate oligosaccharide on it, we flowed
    ApoE over it," said Mah. "We were quite surprised to see that it had a
    binding pattern that looked very similar to Tau protein. It binds very
    well to the 3- O sulfated structures." Tau protein is implicated in
    many neurogenerative diseases, including Alzheimer's.

    The team's findings point to a new potential drug target to slow the
    progress of the disease: the enzymes responsible for sulfation called
    heparan sulfate 3- O transferases.

    Next, the team plans to take a deeper look at ApoE/HS interaction by
    developing a 3D structural model of ApoE-HS interaction and examining
    this interaction in cell cultures and animal models.

    "Alzheimer's disease is very complex with so many aspects," said
    Wang. "The more I study it, the more interesting it gets." "Ultimately,
    we want to prevent or mitigate enough of the symptoms of Alzheimer's
    disease so people can continue to live independently," added Mah.

    "Understanding how the disease works on a molecular basis is really
    critical to finding new treatments." "As our population ages,
    Dr. Wang's research on Alzheimer's disease is increasingly significant,"
    said Deepak Vashishth, director of Rensselaer's Shirley Ann Jackson,
    Ph.D. Center for Biotechnology and Interdisciplinary Studies, of which
    Wang is a member. "The identification of a new potential drug target
    to fight this progressive disease is enormously exciting for not only
    the six million patients in the United States, but for their families
    and caregivers." Wang and Mah were joined in research by Rensselaer Polytechnic Institute's Ashely Canning, James Gibson, Fuming Zhang, and
    Robert J. Linhardt. Yongmei Xu, Xuehong Song, and Lianchun Wang of the University of South Florida contributed, along with Guowei Su and Jian
    Liu of Glycan Therapeutics; Jing Zhao of China Agricultural University;
    and Yongmei Xu, Eduardo Stancanelli, and Jian Liu of University of North Carolina at Chapel Hill.

    * RELATED_TOPICS
    o Health_&_Medicine
    # Alzheimer's_Research # Healthy_Aging #
    Diseases_and_Conditions
    o Mind_&_Brain
    # Alzheimer's # Caregiving # Dementia
    o Matter_&_Energy
    # Biochemistry # Organic_Chemistry # Microarrays
    * RELATED_TERMS
    o Prion o Excitotoxicity_and_cell_damage o
    Dementia_with_Lewy_bodies o Collagen o Alzheimer's_disease o
    Drug_discovery o Psychopharmacology o Enzyme

    ========================================================================== Story Source: Materials provided by
    Rensselaer_Polytechnic_Institute. Original written by Katie
    Malatino. Note: Content may be edited for style and length.


    ========================================================================== Journal Reference:
    1. Dylan Mah, Yanan Zhu, Guowei Su, Jing Zhao, Ashely Canning,
    James Gibson,
    Xuehong Song, Eduardo Stancanelli, Yongmei Xu, Fuming Zhang,
    Robert J.

    Linhardt, Jian Liu, Lianchun Wang, Chunyu
    Wang. Apolipoprotein E Recognizes Alzheimer's Disease
    Associated 3‐ O Sulfation of Heparan Sulfate. Angewandte
    Chemie International Edition, 2023; DOI: 10.1002/ anie.202212636 ==========================================================================

    Link to news story: https://www.sciencedaily.com/releases/2023/05/230524181929.htm

    --- up 1 year, 12 weeks, 2 days, 10 hours, 50 minutes
    * Origin: -=> Castle Rock BBS <=- Now Husky HPT Powered! (1:317/3)